Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 23 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 12/4/2007 First Published: 10/14/2006


1.		Phase III Randomized Study of Irinotecan Hydrochloride With Versus Without Panitumumab or Cyclosporine in Patients With Fluorouracil-Resistant Advanced or Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				CTRU-PICCOLO-MO-05-7289 EUDRACT-2005-003492-20, CTAAC-CTRU-PICCOLO-MO-05-7289, AMGEN-CTRU-PICCOLO-MO-05-7289, EU-20647, NCT00389870


2.		SPECTRUM: Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				20050251 SPECTRUM, 20050251, NCT00460265

First Published: 3/27/2008


3.		Phase III Randomized Pilot Study of Neoadjuvant and Adjuvant Fluorouracil and Oxaliplatin With or Without Panitumumab in Patients With Resectable High-Risk Colon Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				Any age				Other				BCTU-FOXTROT-001 BCTU-FOxTROT-001, ISCRTN 87163246, EUDRACT 2007-001987-55, EU-20830, MREC-07/S0703/57, UKCRN 3771, NCT00647530


4.		Study to Evaluate AMG 706 with or without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				20040153 NCT00094835


5.		Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 82				Other				Pro00002207 SPS 151596, NCT00578071


6.		AMG 655/Panitumumab Combination Metastatic Colorectal Cancer Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				20060332 NCT00630786


7.		Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				07326 NCT00667420


8.		ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				20030250 NCT00089635


9.		SPIRITT - Q2W FOLFIRI Regimen Plus Panitumumab or a Q2W FOLFIRI Regimen Plus Bevacizumab for 2nd-Line mCRC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				20060141 NCT00418938


10.		PRISM (Panitumumab Regimen In Second-Line Monotherapy of Head and Neck Cancer)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				20062088 NCT00446446

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute